IL17A and colitis: In this study, for the first time, we showed that oral treatment of LFS-01 can reverse the development of DSS-colitis by selectively suppressing the harmful enteric pathogens and promoting the Lactobacillus population accompanied with a significant increase of IL-17+γδT cells.